BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Daiichi Sankyo
Fish and Richardson
Fuji
Baxter
Colorcon
Citi
McKinsey
Chinese Patent Office
Queensland Health

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,071,075

« Back to Dashboard

Which drugs does patent 8,071,075 protect, and when does it expire?

Patent 8,071,075 protects AXIRON and is included in one NDA.

This patent has thirty-two patent family members in thirteen countries.
Summary for Patent: 8,071,075
Title:Dermal penetration enhancers and drug delivery systems involving the same
Abstract: The invention relates to a method for treatment or prophylaxis of a disease or condition in an animal comprising administering to a mucosal membrane of said animal in need of such treatment a therapeutically effective amount of a drug delivery system comprising at least one physiologically active agent or prodrug thereof and at least one penetration enhancer selected from safe ester sunscreens.
Inventor(s): Reed; Barry Leonard (Strathmore, AU), Morgan; Timothy Matthias (Parkville, AU), Finnin; Barrie Charles (Glen Iris, AU)
Assignee: Acrux DDS Pty Ltd. (West Melbourne, Victoria, AU)
Application Number:11/905,926
Patent Claim Types:
see list of patent claims
Compound; Delivery; Use;

Drugs Protected by US Patent 8,071,075

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eli Lilly And Co AXIRON testosterone SOLUTION, METERED;TRANSDERMAL 022504-001 Nov 23, 2010 DISCN Yes No ➤ Subscribe ➤ Subscribe Y TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,071,075

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPN 8144Feb 19, 1996

Non-Orange Book US Patents Family Members for Patent 8,071,075

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,923,983 Transdermal delivery of hormones ➤ Subscribe
7,438,203 Dermal penetration enhancers and drug delivery systems involving same ➤ Subscribe
6,299,900 Dermal penetration enhancers and drug delivery systems involving same ➤ Subscribe
6,998,138 Topical delivery of anti-alopecia agents ➤ Subscribe
6,818,226 Dermal penetration enhancers and drug delivery systems involving same ➤ Subscribe
6,929,801 Transdermal delivery of antiparkinson agents ➤ Subscribe
6,916,487 Transdermal delivery of antiemetics ➤ Subscribe
6,916,486 Transdermal delivery of analgesics ➤ Subscribe
7,387,789 Transdermal delivery of non-steroidal anti-inflammatory drugs ➤ Subscribe
6,964,777 Transdermal delivery of antianxiety agents ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,071,075

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 1769785 ➤ Subscribe
Portugal 1674068 ➤ Subscribe
Portugal 901368 ➤ Subscribe
New Zealand 330942 ➤ Subscribe
Luxembourg 91973 ➤ Subscribe
Luxembourg 91972 ➤ Subscribe
Luxembourg 91971 ➤ Subscribe
Japan 2007326867 ➤ Subscribe
Japan 4213211 ➤ Subscribe
Japan 2000504697 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Healthtrust
Teva
Medtronic
Boehringer Ingelheim
Chubb
Moodys
McKesson
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot